Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 675 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Steatoses Clear all
Recruiting Phase 1 Interventional

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815
View directory record Official record
Conditions
NON-ALCOHOLIC STEATOHEPATITIS
Interventions
DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Coronado, California • Montclair, California • Panorama City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 3, 2026, 3:10 PM EDT
Active, not recruiting Phase 2 Interventional

Tocotrienol Against the Progression of End Stage Liver Disease

NCT02581085
View directory record Official record
Conditions
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Tocotrienol (TCT), Placebo
Drug · Other
Lead sponsor
Chandan Sen
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

NCT05591079
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
CS0159 (Linafexor)
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
17
States / cities
Gardena, California • Huntington Park, California • Panorama City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Withdrawn No phase listed Observational

Evaluation of Intestinal Microbiome in Obese Kids

NCT00816296
View directory record Official record
Conditions
Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Blood Draw, Stool collection, BodPod Measurement, Liver Ultrasound
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Sep 3, 2026, 3:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions

NCT06932289
View directory record Official record
Conditions
NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
Dietary Supplement · Device
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07732400
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
VV-14303
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chandler, Arizona • Lady Lake, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

NCT06195943
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
Interventions
Exercise Intervention with use of El-Fit App
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 3, 2026, 3:10 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
80
States / cities
Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

NCT04841057
View directory record Official record
Conditions
Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
Interventions
50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

NCT01645852
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Hepatic Steatosis, Steatohepatitis
Interventions
Optifast 800
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 3, 2026, 3:10 PM EDT
Not listed No phase listed Observational

Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease

NCT05908006
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur
Device
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Flowood, Mississippi • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Active, not recruiting Not applicable Interventional

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

NCT06735924
View directory record Official record
Conditions
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Low-oxalate fixed diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Not applicable Interventional Results available

Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease

NCT04576923
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis
Interventions
Velacur by Sonic Incytes
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Conditionally Increased Output (CIO) Enhanced Ultrasound System

NCT05792423
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions
GE ultrasound system with increased acoustic output settings
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Completed No phase listed Observational Results available

Controlled Attenuation Parameter (CAP) in Liver Allografts

NCT02798861
View directory record Official record
Conditions
Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction
Interventions
Fibroscan 402/530
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Little Rock, Arkansas • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05006885
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
124
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional Results available

Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)

NCT00586313
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Tru-cut biopsy, Tru-cut
Device · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 3, 2026, 3:10 PM EDT